| 1/24 | Identification of a Novel Immunometabolic Target and Agonist for PLXDC2 for Amelioration of DSS Colitis Model in Mice. (opens in a new tab) Journal of Crohn's and Colitis, Volume 18, Issue Supplement 1. (Publication P086). January 2024.
|
|---|
| 1/24 | The Effect of NLRX1 Activation on Eosinophils in Ulcerative Colitis and Inflammation: Translational Learnings Across Diseases and from Mouse to Human. (opens in a new tab) Journal of Crohn's and Colitis, Volume 18, Issue Supplement 1. (Publication P571). January 2024.
|
|---|
| 1/24 | Role of NLRX1 Agonist NX-13 in Reducing Visceral Hypersensitivity in Preclinical Gastrointestinal Inflammation. (opens in a new tab) Journal of Crohn's and Colitis, Volume 18, Issue Supplement 1. (Publication P114). January 2024.
|
|---|
| 1/24 | Translating Pharmacokinetic and Efficacy Outcomes of NLRX1 Agonist NX-13: Contrasting a Pig Model and a Human Phase 1b Clinical Trial in Ulcerative Colitis. (opens in a new tab) Journal of Crohn's and Colitis, Volume 18, Issue Supplement 1. (Publication P739). January 2024.
|
|---|
| 1/24 | The Immunometabolic Bimodal Mechanism of NLRX1 Agonist NX-13 in a Pig Model of Ulcerative Colitis. (opens in a new tab) Journal of Crohn's and Colitis, Volume 18, Issue Supplement 1. (Publication P739). January 2024.
|
|---|
| 1/24 | Modulation of Immunometabolism via NLRX1 or PLXDC2: Novel Bimodal Mechanisms for the Treatment of Inflammatory Bowel Diseases. (opens in a new tab) Journal of Crohn's and Colitis, Volume 18, Issue Supplement 1. (Publication P144). January 2024.
|
|---|
| 11/23 | The Safety, Tolerability, Pharmacokinetics and Clinical Efficacy of the NLRX1 agonist NX-13 in Active Ulcerative Colitis: Results of a Phase 1b Study. (opens in a new tab) Journal of Crohn's and Colitis. e-published ahead of print . November 2023.
|
|---|
| 10/23 | Target Engagement And Pharmacodynamic Molecular Mechanism Evaluation In A Phase 1b Study of the Nucleotide-binding Oligomerization Domain, Leucine Rich Repeat Containing X1 (NLRX1) Agonist NX-13 in Ulcerative Colitis. (opens in a new tab) UEG Week Journal Abstracts 2023; Poster Presentations – United European Gastroenterology Journal (11) S8. (Publication PP785 / p975). October 2023.
|
|---|
| 10/23 | Symptomatic Relief Is Correlated with Early Endoscopic Response to the Nucleotide-Binding Oligomerization Domain, Leucine Rich Repeat Containing X1 (NLRX1) Agonist NX-13 In Ulcerative Colitis: Results in a Phase 1b Study. (opens in a new tab) UEG Week Journal Abstracts 2023; Poster Presentations – United European Gastroenterology Journal (11) S8. (Publication OP104 / p103). October 2023.
|
|---|
| 10/23 | The Nucleotide-Binding Oligomerization Domain, Leucine Rich Repeat Containing X1 (NLRX1) Agonist NX-13 Demonstrates Rapid Symptomatic and Biomarkers Improvement in Ulcerative Colitis: Results In a Phase 1b Study. (opens in a new tab) UEG Week Journal Abstracts 2023; Poster Presentations – United European Gastroenterology Journal (11) S8. (Publication OP078 / p76). October 2023.
|
|---|
| 2/23 | A Phase 1b Study to Evaluate Safety, Tolerability, Pharmacokinetics and Clinical Efficacy of the Nucleotide-binding oligomerization domain, Leucine rich Repeat containing X1 (NLRX1) agonist NX-13 in Ulcerative Colitis. (opens in a new tab) Journal of Crohn's and Colitis, Volume 17, Issue Supplement 1. (Publication P577). February 2023.
|
|---|
| 10/21 | Safety and Tolerability of NX-13 in a Randomized, Double-Blind Placebo Controlled Phase I Study in Normal Healthy Volunteers. (opens in a new tab) Safety and Tolerability of NX-13 in a Randomized, Double-Blind Placebo Controlled Phase I Study in Normal Healthy Volunteers. (Publication P0480). October 2021.
|
|---|
| 11/19 | Activation of NLRX1 by NX-13 Alleviates Inflammatory Bowel Disease through Immunometabolic Mechanisms in CD4+ T Cells. (opens in a new tab) The Journal of Immunology. November 6, 2019.
|
|---|
| 6/19 | Exploratory studies with NX-13: oral toxicity and pharmacokinetics in rodents of an orally active, gut-restricted first-in-class therapeutic for IBD that targets NLRX1. (opens in a new tab) Drug and Chemical Toxicology . June 10, 2019 .
|
|---|
| 5/19 | Su1818 – Preclinical Efficacy and Safety of Nx-13: A Novel Nlrx1-Targeting Immunometabolic Therapeutic for Crohn’s Disease and Ulcerative Colitis. (opens in a new tab) AGA Journals . May 2019.
|
|---|
| 2/18 | NLRX1 Modulates Immunometabolic Mechanisms Controlling the Host-Gut Microbiota Interactions during Inflammatory Bowel. (opens in a new tab) Disease Front Immunol. February 2018.
|
|---|
| 3/17 | NLRX1 Regulates Effector and Metabolic Functions of CD4+ T Cells. (opens in a new tab) J Immunol. March 2017.
|
|---|
